LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma
Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
A Phase I, Multicenter study to evaluate the safety, tolerability, and Efficacy of LCAR-T2C
CAR-T cells in relapsed or refractory CD4+T Lymphocyte Tumor Patients.
Phase:
Phase 1
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Collaborator:
Nanjing Legend Biotechnology Co. The First Affiliated Hospital of USTC west district；The First Affiliated Hospital of the Air Force Medical University